APLS Stock Recent News
APLS LATEST HEADLINES
Apellis Pharmaceuticals Inc (NASDAQ: APLS) is down nearly 40% versus its year-to-date high but a Mizuho analyst does not see it as an opportunity to buy per se. Mizuho remains ‘neutral' on Apellis Pharmaceuticals stock Graig Suvannavejh reiterated his “neutral” stance on the biotech stock in a recent research note.
Apellis Pharmaceuticals (APLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Apellis' (APLS) fourth-quarter 2023 bottom line misses estimates, while the top line meets the same. The newly approved product, Syfovre, drives year-over-year sales.
While the top- and bottom-line numbers for Apellis Pharmaceuticals, Inc. (APLS) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Apellis Pharmaceuticals, Inc. (APLS) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compares to loss of $1.50 per share a year ago.
WALTHAM, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq: APLS) today announced that the company will participate in the following March investor conferences:
Apellis (APLS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Apellis Pharmaceuticals, Inc. (APLS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
WALTHAM, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its fourth quarter and full year 2023 financial results on Tuesday, February 27, 2024, at 8:30 a.m. ET.
Here is how Apellis Pharmaceuticals, Inc. (APLS) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.